These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 33062233)

  • 1. Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease.
    Osunkwo I; Manwani D; Kanter J
    Ther Adv Hematol; 2020; 11():2040620720955000. PubMed ID: 33062233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contemporary Management and Prevention of Vaso-Occlusive Crises (VOCs) in Adults With Sickle Cell Disease.
    Weaver SB; Rungkitwattanakul D; Singh D
    J Pharm Pract; 2023 Feb; 36(1):139-148. PubMed ID: 34151636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso-occlusive Pain Crises in Patients with Sickle Cell Disease.
    Han J; Saraf SL; Gordeuk VR
    Pharmacotherapy; 2020 Jun; 40(6):535-543. PubMed ID: 32350885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review.
    Dick MH; Abdelgadir A; Kulkarni VV; Akram H; Chatterjee A; Pokhrel S; Khan S
    Cureus; 2022 May; 14(5):e24920. PubMed ID: 35706735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sickle Cell Disease: A Review.
    Kavanagh PL; Fasipe TA; Wun T
    JAMA; 2022 Jul; 328(1):57-68. PubMed ID: 35788790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between Vaso-occlusive Crises and Opioid Prescriptions among Patients with Sickle Cell Disease: A Retrospective Claims-based Study.
    Kang HA; Barner JC; Richards KM; Bhor M; Paulose J; Kutlar A
    J Health Econ Outcomes Res; 2020; 7(1):94-101. PubMed ID: 32685602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Vaso-Occlusive Crises and Opioid Prescriptions Among Patients with Sickle Cell Disease: A Retrospective Claims-Based Study.
    Kang HA; Barner JC; Richards KM; Bhor M; Paulose J; Kutlar A
    J Health Econ Outcomes Res; 2020; 7(1):94-101. PubMed ID: 36873574
    [No Abstract]   [Full Text] [Related]  

  • 8. Profile of crizanlizumab and its potential in the prevention of pain crises in sickle cell disease: evidence to date.
    Riley TR; Riley TT
    J Blood Med; 2019; 10():307-311. PubMed ID: 31507334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sickle cell disease as a vascular disorder.
    Ofori-Acquah SF
    Expert Rev Hematol; 2020 Jun; 13(6):645-653. PubMed ID: 32362160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crizanlizumab in sickle cell disease.
    Kaur K; Kennedy K; Liles D
    Pain Manag; 2023 Oct; ():. PubMed ID: 37850353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic literature review of frequency of vaso-occlusive crises in sickle cell disease.
    Zaidi AU; Glaros AK; Lee S; Wang T; Bhojwani R; Morris E; Donohue B; Paulose J; Iorga ŞR; Nellesen D
    Orphanet J Rare Dis; 2021 Nov; 16(1):460. PubMed ID: 34727959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging Therapies for the Management of Pain and Vaso-Occlusive Crises in Patients With Sickle Cell Disease: A Systematic Review of Randomized Controlled Trials.
    Lowe M; Bambhroliya Z; Patel H; Patel VJ; Vudugula SA; Cheruvu NP; Raza S; Okunlola OI
    Cureus; 2023 Apr; 15(4):e38014. PubMed ID: 37223201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advancements in Sickle Cell Disease (SCD) Treatment: A Review of Novel Pharmacotherapies and Their Impact on Patient Outcomes.
    Khan SJ; Zaidi SAT; Murtaza SF; Asif M; Kumar V
    Cureus; 2023 Aug; 15(8):e42847. PubMed ID: 37664319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Advances in Sickle-Cell Disease Therapies: A Review of Voxelotor, Crizanlizumab, and L-glutamine.
    Migotsky M; Beestrum M; Badawy SM
    Pharmacy (Basel); 2022 Sep; 10(5):. PubMed ID: 36287444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The vaso-occlusive pain crisis in sickle cell disease: Definition, pathophysiology, and management.
    Darbari DS; Sheehan VA; Ballas SK
    Eur J Haematol; 2020 Sep; 105(3):237-246. PubMed ID: 32301178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic and Clinical Burden of Managing Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in the United States.
    Udeze C; Evans KA; Yang Y; Lillehaugen T; Manjelievskaia J; Mujumdar U; Li N; Andemariam B
    Adv Ther; 2023 Aug; 40(8):3543-3558. PubMed ID: 37332020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of l-glutamine versus crizanlizumab for adults with sickle cell disease: model focused on reducing pain episode costs from Qatar's healthcare perspective.
    Adel AM; Abushanab D; Al-Badriyeh D; Hamad A; Alshurafa A; Yassin MA
    SAGE Open Med; 2024; 12():20503121231224551. PubMed ID: 38711465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease: A Randomized Clinical Trial.
    Casella JF; Barton BA; Kanter J; Black LV; Majumdar S; Inati A; Wali Y; Drachtman RA; Abboud MR; Kilinc Y; Fuh BR; Al-Khabori MK; Takemoto CM; Salman E; Sarnaik SA; Shah N; Morris CR; Keates-Baleeiro J; Raj A; Alvarez OA; Hsu LL; Thompson AA; Sisler IY; Pace BS; Noronha SA; Lasky JL; de Julian EC; Godder K; Thornburg CD; Kamberos NL; Nuss R; Marsh AM; Owen WC; Schaefer A; Tebbi CK; Chantrain CF; Cohen DE; Karakas Z; Piccone CM; George A; Fixler JM; Singleton TC; Moulton T; Quinn CT; de Castro Lobo CL; Almomen AM; Goyal-Khemka M; Maes P; Emanuele M; Gorney RT; Padgett CS; Parsley E; Kronsberg SS; Kato GJ; Gladwin MT
    JAMA; 2021 Apr; 325(15):1513-1523. PubMed ID: 33877274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamics of von Willebrand factor reactivity in sickle cell disease during vaso-occlusive crisis and steady state.
    Sins JWR; Schimmel M; Luken BM; Nur E; Zeerleder SS; van Tuijn CFJ; Brandjes DPM; Kopatz WF; Urbanus RT; Meijers JCM; Biemond BJ; Fijnvandraat K
    J Thromb Haemost; 2017 Jul; 15(7):1392-1402. PubMed ID: 28457019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An innovative intervention for the prevention of vaso-occlusive episodes in sickle cell disease.
    Jeon WJ; Joung B; Moon JH; Hino C; Park D; Pham B; Castillo DR; Chong E; Kaur S; Grismore C; Cao H
    Hematology; 2023 Dec; 28(1):2215575. PubMed ID: 37227254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.